A new treatment for alcoholic hepatitis using a specific drug
An innovative, non-thiazolidinedione pan-PPAR agonist therapeutic for alcoholic hepatitis: IND-enabling safety and toxicological evaluation
This study is testing a new oral medication called PLG888 to see if it can help people with alcoholic hepatitis, a serious liver condition caused by drinking too much alcohol, and it might work better and have fewer side effects than current treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pleiogenix INC. NIH-funded |
| Lab location | 1 site (Carlsbad, United States) |
| Project ID | NIH-11007310 on NIH RePORTER |
What this research studies
This research focuses on developing a novel oral medication, PLG888, aimed at treating alcoholic hepatitis, a severe liver disease caused by excessive alcohol consumption. The approach involves a unique mechanism that selectively activates certain receptors in the body to improve liver function and survival rates. The study has shown promising results in animal models, indicating that this treatment could be more effective than current options, which often have significant side effects. Patients participating in this research may receive this innovative therapy as part of the evaluation process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcoholic hepatitis, particularly those who are heavy alcohol drinkers.
Not a fit: Patients with alcoholic hepatitis who are not heavy drinkers or those who have other underlying liver conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from alcoholic hepatitis, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown success with similar receptor-targeting approaches in liver diseases, suggesting potential for this novel treatment.
Where this research is happening
Carlsbad, United States
- Pleiogenix INC. — Carlsbad, United States (Active)
Researchers
- Principal investigator: Manchem, Prasad — Pleiogenix INC.
- Study coordinator: Manchem, Prasad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.